Y-mAbs Details Executive Equity Awards in DEF 14A Filing
| Field | Detail |
|---|---|
| Company | Y-Mabs Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | May 30, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Executive Compensation, Equity Awards, DEF 14A, Biotechnology, Pharmaceuticals, Corporate Governance, SEC Filings
TL;DR
**Y-mAbs' executive compensation filing is a snooze, showing zero equity awards for key execs in 2023 and 2024, which is either a red flag or incomplete data.**
AI Summary
Y-mAbs Therapeutics' DEF 14A filing primarily details executive compensation for the fiscal years ending December 31, 2023, and December 31, 2024. The filing highlights equity awards granted to named executive officers, including Mr. Rossi and Mr. Gad. For 2024, Mr. Rossi's equity awards reported in the Summary Compensation Table were $0, with year-end fair value of outstanding and unvested equity awards granted in 2024 also at $0. In contrast, for 2023, Mr. Rossi received equity awards valued at $0 in the Summary Compensation Table, while Mr. Gad also received $0 in equity awards for the same period. The document focuses on the structure and valuation of these equity awards, including adjustments and changes in fair value of outstanding awards from prior years. The strategic outlook is implied through the compensation structure, aiming to incentivize long-term performance, though specific revenue or net income figures are not provided in this particular excerpt. Risks are not explicitly detailed in this compensation-focused section.
Why It Matters
This DEF 14A filing provides transparency into Y-mAbs Therapeutics' executive compensation practices, particularly regarding equity awards for key executives like Mr. Rossi and Mr. Gad. For investors, understanding how executives are incentivized through equity can signal alignment with shareholder interests and long-term company performance. Employees might view these compensation structures as benchmarks for their own potential growth within the company. In the competitive pharmaceutical industry, attractive compensation packages are crucial for retaining top talent, impacting the company's ability to innovate and bring new therapies to market. The lack of specific dollar values for equity awards in the provided excerpt for 2023 and 2024 could raise questions about the full scope of executive incentives.
Risk Assessment
Risk Level: medium — The risk level is medium because the provided data shows $0 for equity awards in the Summary Compensation Table for both Mr. Rossi and Mr. Gad in 2023 and 2024. This could indicate a lack of direct equity incentive for these key executives during those periods, or it could be an incomplete data set, both of which present a risk to investor understanding of executive alignment and motivation.
Analyst Insight
Investors should scrutinize the full DEF 14A filing to understand the complete executive compensation package, especially the actual dollar values of equity awards and any other forms of compensation not detailed in this excerpt. Seek clarification on the $0 equity award figures for 2023 and 2024 to assess executive incentives and potential dilution from other equity grants.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Mr. Rossi | Named Executive Officer | $0 |
| Mr. Gad | Named Executive Officer | $0 |
Key Numbers
- $0 — Equity Awards in Summary Compensation Table for Mr. Rossi (for 2024, indicating no reported equity compensation in this specific table)
- $0 — Year-End Fair Value of Outstanding and Unvested Equity Awards for Mr. Rossi (granted in 2024, suggesting no new unvested awards from that year)
- $0 — Equity Awards in Summary Compensation Table for Mr. Rossi (for 2023, indicating no reported equity compensation in this specific table)
- $0 — Equity Awards in Summary Compensation Table for Mr. Gad (for 2023, indicating no reported equity compensation in this specific table)
- 2025-05-30 — Filed As Of Date (date the DEF 14A was filed with the SEC)
- 2025-07-11 — Conformed Period of Report (the period to which the filing relates)
- 001-38650 — SEC File Number (unique identifier for Y-mAbs' SEC filings)
- 1934 Act — SEC Act (the act under which the filing is made)
- 21 — Public Document Count (number of documents in the filing)
- 1231 — Fiscal Year End (Y-mAbs Therapeutics' fiscal year ends on December 31st)
Key Players & Entities
- Y-mAbs Therapeutics, Inc. (company) — filer of DEF 14A
- Mr. Rossi (person) — named executive officer
- Mr. Gad (person) — named executive officer
- SEC (regulator) — governing body for filings
- Bloomberg (company) — financial news outlet
- 03 Life Sciences (company) — organization name
- Princeton, NJ (location) — business address
- 2024-01-01 (date) — start of fiscal year for compensation data
- 2024-12-31 (date) — end of fiscal year for compensation data
- 2023-01-01 (date) — start of fiscal year for compensation data
FAQ
What is the purpose of Y-mAbs Therapeutics' DEF 14A filing?
The DEF 14A filing by Y-mAbs Therapeutics is a definitive proxy statement, primarily used to provide shareholders with information regarding matters to be voted upon at an upcoming meeting, including details on executive compensation and corporate governance.
Which executives are mentioned in Y-mAbs Therapeutics' DEF 14A regarding compensation?
The DEF 14A filing specifically mentions Mr. Rossi and Mr. Gad as named executive officers for whom equity award compensation data is provided for the fiscal years 2023 and 2024.
What were the reported equity awards for Mr. Rossi in 2024 according to the Y-mAbs filing?
For 2024, Mr. Rossi's equity awards reported in the Summary Compensation Table were $0, and the year-end fair value of outstanding and unvested equity awards granted in 2024 was also $0.
How did Mr. Gad's equity awards compare in 2023 for Y-mAbs Therapeutics?
In 2023, Mr. Gad's equity awards reported in the Summary Compensation Table for Y-mAbs Therapeutics were $0, similar to Mr. Rossi's reported amount for the same period.
What is the significance of $0 equity awards for Y-mAbs executives?
The reported $0 for equity awards in the Summary Compensation Table for key Y-mAbs executives in 2023 and 2024 could indicate that equity compensation was structured differently, not reported in this specific table, or that no new equity was granted, which could impact executive incentives and investor perception.
When was Y-mAbs Therapeutics' DEF 14A filing submitted?
Y-mAbs Therapeutics' DEF 14A filing was submitted to the SEC on May 30, 2025, with a conformed period of report of July 11, 2025.
What industry does Y-mAbs Therapeutics operate in?
Y-mAbs Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, classified under Standard Industrial Classification code 2834.
Where is Y-mAbs Therapeutics' business located?
Y-mAbs Therapeutics' business address is 202 Carnegie Center, Suite 301, Princeton, NJ 08540.
What are the potential risks associated with the compensation data in this Y-mAbs filing?
A potential risk is that the $0 equity award figures for 2023 and 2024 for named executives might not reflect the full scope of their compensation, potentially misleading investors about executive incentives and alignment with long-term shareholder value.
How can investors get more detailed information on Y-mAbs Therapeutics' executive compensation?
Investors should review the complete DEF 14A filing on the SEC's EDGAR database, using the accession number 0001558370-25-008299, to find comprehensive details on all components of executive compensation.
Industry Context
Y-mAbs Therapeutics operates in the biopharmaceutical sector, focusing on developing antibody-based therapies for cancer. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on equity-based compensation to attract and retain specialized talent, especially given the inherent risks and potential for high rewards associated with drug development.
Regulatory Implications
As a biopharmaceutical company, Y-mAbs is subject to stringent regulations from bodies like the FDA. While this DEF 14A filing focuses on executive compensation, any future regulatory setbacks or approvals can significantly impact the company's valuation and, consequently, the perceived value and performance of executive equity awards.
What Investors Should Do
- Review the compensation philosophy for alignment with long-term value creation.
- Monitor future filings for changes in executive compensation and equity grants.
- Assess the company's clinical and commercial progress independently.
Key Dates
- 2025-05-30: DEF 14A Filing Date — Indicates the date the proxy statement was officially submitted to the SEC.
- 2025-07-11: Conformed Period of Report — Defines the reporting period the filing pertains to, which is crucial for understanding the context of the disclosed information.
- 2024-12-31: Fiscal Year End — Marks the end of the financial year for which compensation and other company data are reported.
- 2023-12-31: Fiscal Year End — Marks the end of the prior financial year, relevant for comparative analysis of compensation and performance.
Glossary
- DEF 14A
- A proxy statement filing required by the SEC for publicly traded companies, typically filed before annual shareholder meetings to provide information on matters to be voted on, including executive compensation. (This is the primary document type being analyzed, detailing executive compensation and related corporate governance matters.)
- Summary Compensation Table
- A table within the DEF 14A that summarizes the compensation of the company's named executive officers for the last three fiscal years. (Key data on executive compensation, including salary, bonus, stock awards, and other compensation, is presented here. Notably, for Y-mAbs, equity awards for key executives were reported as $0 for the periods covered.)
- Equity Awards
- Awards granted to employees, typically executives, in the form of company stock or options, intended to align their interests with shareholders and incentivize performance. (The filing extensively discusses equity awards granted to named executive officers, detailing their valuation and changes in fair value.)
- Fair Value of Outstanding and Unvested Equity Awards
- The estimated market value of equity awards that have been granted but have not yet vested as of a specific date. (This metric is important for understanding the potential future value of executive compensation and is reported as $0 for Mr. Rossi's 2024 grants.)
- Named Executive Officers (NEOs)
- The top executive officers of a company, typically the CEO, CFO, and the next three highest-paid executive officers, whose compensation is disclosed in detail in SEC filings. (Mr. Rossi and Mr. Gad are identified as NEOs, and their compensation details are the focus of this DEF 14A filing.)
Year-Over-Year Comparison
This DEF 14A filing focuses on executive compensation for the fiscal years ending December 31, 2023, and 2024. A key observation is the reported $0 in equity awards for Mr. Rossi and Mr. Gad in the Summary Compensation Table for these periods. This contrasts with potential prior year grants or different compensation components not detailed here. Without comparative data on revenue, net income, or other financial performance metrics from previous filings, a direct year-over-year comparison of overall financial health or compensation trends is not possible based solely on this excerpt.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 30, 2025 by Mr. Rossi regarding Y-mAbs Therapeutics, Inc..